Table 3.
Summary of recent reported H2S-activated probes in CRC.
| H2S probe | Imaging method | Signal detection | Detection limit | In vivo Experimental subject |
|---|---|---|---|---|
| AzMC | Visible light | 450 nm | 200 nM | – |
| AM-BODIPY-NBD | Visible light | 520 nm | 15.7 nM | – |
| TPANF | Visible light | 468 nm | 170 nM | HCT116 tumor mice |
| Probe 1 | NIR-I | 796 nm | 39.6 nM | HCT116, HT29 tumor mice |
| Ag-CEW | NIR-II | 1090 nm | 35 nM | HCT116 tumor mice |
| NanoBOD-SCM | NIR-I | 710/610 nm | 198 nM | – |
| NIR-II@Si | NIR-II | 700/900 nm | 37 nM | HCT116 tumor mice |
| DCNP@HSA-Ag+ | NIR-II | 1050/1550 nm | 210 μM | MC38-luc tumor mice |
| F12+-ANP | Afterglow luminescent | 790 nm | 100 nM | – |
| TPAMC-UCNPs@PEG | UCL | 540/800 nm | 220 nM | HCT116 tumor mice |
| Si@BODPA | PA | 780 nm | 53 nM | HCT116 tumor mice |
| AzHD-LP | PA | 680 nm | 500 nM | HCT116 tumor mice |
| NR-NO2 | PA | 710 nm | 40 nM | HCT116 tumor mice |
| [99mTc]Tc-Gluconate | SPECT | gamma-ray | – | – |
| Fe3O4@Cu2O-lipid-mPEG | PA; MRI | 770–1100 nm; MRI signals | 110/4.10 μM; 214/2.15 μM (wide/narrow concentration ranges) | HCT116 tumor mice |
| Amphiphilic probes 1 and 2 | PA; NIR-I | 718 nm | 60 nM | HCT116 tumor mice |
| SiO2@Ag | PA; NIR-II | 1000–1400 nm | 0.92 nM | HCT116 tumor mice |